Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RDAR... Let the Chase begin.... live meeting at 4:30 today....
Raadr Inc., doing business as Telvantis, Schedules Virtual Investor Call to Review
Q1’25, Strategic Milestones and Future Outlook
New York – May 28, 2025 – Raadr Inc. (OTC: RDAR), doing business as Telvantis
("Telvantis" or the "Company"), a leading technology-driven telecommunications and
enterprise solutions provider, today announced details of its upcoming virtual investor call
scheduled for Monday, June 2, 2025, at 4:30 PM Eastern Time.
This virtual meeting will provide investors with key insights into Telvantis’ first quarter
performance, recent strategic initiatives, significant financial achievements, and detailed
plans for future growth. Telvantis leadership will deliver an informative update, followed by a
dedicated question-and-answer session.
Investors not yet registered for the Ambassador Program can sign up here:
https://telvantis.com/email-alerts/.
Upon registration, attendees will receive a confirmation email with instructions on how to join the
meeting. Investors are encouraged to register early to secure their spot and may submit
questions in advance by emailing ir@telvantis.com with the subject line "Investor Call
Question" by May 30, 2025.
"Transparent communication with our shareholders and investors is paramount at Telvantis,"
said Daniel Contreras, CEO of Telvantis. "We look forward to sharing tangible progress on
our strategic initiatives, highlighting our recent achievements, and outlining our roadmap for
continued growth. This meeting is a great opportunity to engage directly with our investors,
address their questions, and reaffirm our commitment to long-term shareholder value."
Event Details:
? Date: Monday, June 2, 2025
? Time: 4:30 PM Eastern Time
? Platform: Online (registration required)
? Registration Link (if not yet registered for the Ambassador Program):
https://telvantis.com/email-alerts/
telvantis.com | Telvantis Inc.
ASII.... You don't own this stock? You should......... https://www.otcmarkets.com/stock/IQST/news/IQST---IQSTEL-Sparks-Rapid-Global-Fintech-Expansion-with-GlobeTopper-Acquisition----Fast-Tracking-1-Billion-Growth-Plan?e&id=3251837
TNXP was Up 12.41% yesterday! On last December 17, it did Quickly surge 16.33-Bagger to $194 (Premarket-High) from previous Bottom $11.88 --- see the first chart below!
This Hidden Gem is also at Hyper Oversold status --- from $194 (note, $130 was the daily high after 9:30AM) to Super-Ridiculous-Low Bottom $6.76!
This Diamond_In_Rough has Shocking-High Huge Cash at hand ($132M) and Huge Equity Value ($181M)!
So, TNXP is Super Undervalued now!
TNXP is the Cheapest Bio-Tech NASDAQ stock with Upcoming Key drug (TNX-102 SL) FDA-Approval Day on August 15, 2025!
Easy to surge over its most recent high $130!
There is a Huge Price-Gap between 12/17/24's Premarket-High $194 and Daily-High $130! So, TNXP will explode to over $200 Easily And Quickly!
Note, the current price is Above all the Technical MALs (200-Day, 50-Day, and 20-Day MAL etc.)!
Hopefully the company will issue some Very Good News to trigger the Upcoming 30-Bagger+ GIANT Rally! TNXP is Much-Cheaper than ADHC!
Note, its extra Bio-Tech peer (VINC: 5,234,277 shares FIXED Tiny OS) has $0.85 a share Huge Cash Value and $0.40 a share Huge Book Value plus Up To $12M Intangible IP etc. HUGE Assets Value but at Incredible-Low price $0.0421 now, LOL! Easy to soar to $1.41to match the Same market value with its DELINQUENT-SEC-Reporting peer (TTOO: 28,301,887 shares Large OS) at its most recent high $0.259! VINC had the most recent high $10.4! At Hyper Oversold status! Super Undervalued now!
ADHC share holder update on X today
Keep an eye out for multiple PRs on the way$ADHC Shareholder update out just now!
— Stock Picks NYC (@StockPicksNYC) May 14, 2025
They have a lot going on right now. Keep an eye out for PRs
Also they received a favorable review by the FDA on their Breakthrough Device application a few weeks ago. Glucoguard coming closer to breakthrough device designation by the FDA… https://t.co/X8uoaU44LW
New video covering on ADHC IQSTD TWOH AHRO published on YouTube
New video covering $ADHC, $IQSTD, $AHRO, $TWOH by @PolarizingLit 🔥
— Stock Picks NYC (@StockPicksNYC) May 8, 2025
Here: https://t.co/JKuhury80s
Share the video if you can, thanks https://t.co/XAEromT9N7
RDAR.... Buyback...........: Raadr Inc., Doing Business as Telvantis, Announces $1 Million Share Buyback Program
NEW YORK - May 6, 2025 (NEWMEDIAWIRE) - Raadr Inc. (OTC: $RDAR), doing business as Telvantis ("Telvantis" or the "Company"), today announced the initiation of a share buyback program. The company's board of directors approved an initial purchase of up to $1,000,000 worth of common stock through market purchases.
The share buyback comes as the company's first quarter performance showed strength into the rest of 2025.
"This is the start of another initiative to create long-term value for shareholders," said Daniel Contreras, CEO of Telvantis. "The board believes that our common stock represents an excellent investment opportunity as the company is currently valued significantly below its intrinsic value."
GRCU (7.3B/8B shares High OS/AS) has Bottomed-Out at a Much-Much-Much-Higher New Supporting price $0.0001, instead of its Real Bottom $0.000001! Way-Oversold status! We should see a Quick Bounce to 52-week-high $0.0003 again in the coming weeks...
Anyway, its Red-Hot Bitcoin-Mining Hidden Gem (VTXB: 3.7B/4B shares Low OS/AS) could Easily and Rapidly surge back to its recent highs area $0.0050 ~ $0.0951 again because VTXB (at the Cheapest Bottom $0.0001 now) is a Much-Much-Much-Better Investment-Grade NEVER-R/S Frequently-Paying-Cash-Dividend Super-Undervalued Hyper-Oversold Fully-Reporting Much-Much-Much-Lower-SS Current-Information-tier OTC stock than GRCU!
VTXB is Much-Much-Much Cheaper than RDAR, BIEL, CGAC, NTRR, ATVK, CBTC, MASN, PTEL, SSHT, AFFL, and ALST etc.!
RDAR... NEWS NEWS NEWS Telvantis, Releases the Interview From the Floor of the NYSE on YouTube https://finance.yahoo.com/news/raadr-inc-doing-business-telvantis-123000456.html
RDAR... This is the ONE to own today...... The NYSE floor interview date is set for April 23, 2025. The release of the interview to the public will be on April 30, 2025.
The selection of topics will include the following:
Acquisitions and corporate expansion plans
PCAOB audit updates
Revenues
“Both shareholders and the Company have gone through some amazing transformations over the past few months as we completed Phase 1 and moved on to Phase 2 of our 2025 growth strategy. To be selected for an interview on the floor of the NYSE is an honor and testament to what we are building here at Telvantis,” commented Daniel Gilcher, CFO of Telvantis, who will be representing the Company on the floor of the NYSE.
VINC (Only 5,234,277 shares FIXED Tiny OS, the Extra-NASDAQ Bio-Tech stock) was Up 13.55% yesterday after It Bottomed Out at Mere $235,543 Incredible-Low Market Value! The Cash Alone is $4.987M which does not include $12M worthy Intangible Assets!
This Diamond-In-Rough is Super Undervalued now based on its Huge Positive Cash Value ($0.9542 a share) and Huge Positive Book Value ($0.522 a share)!
This Hidden Gem is also at Hyper Oversold status --- from 12/30/2024's high $10.4 to Ridiculous-Low Bottom $0.045!
Easy to Quickly surge over April 27's high $1.43 because buying its Much-Much-Much-WORSE peer (TTOO has -$12M Huge NEGATIVE Net Asset and 28,301,887 shares Large OS) at April 21's high $0.259 = buying VINC at $1.400421!
Note, the AI application estimates that VINC has $12M worthy Intangible Assets which are not included in the latest financial balance sheet! So, the Real Book Value is $2.82 and the Real cash Value is $3.25!
Wow, buying RDAR (15,925,000,000 shares AS, 6,746,260,661 shares OS, and -$0.00403 Book Value) at its recent high 0.03 = buying VTXB (4,000,000,000 shares AS, 3,787,775,000 shares OS, and -$0.0001 Book Value) at 0.0535 vs. at 99.72% GIANT-Discount Basement price level 0.00015 now!
RDAR heavy volume lately, new DD here
$RDAR DD (Part 1)
— Stock Picks NYC (@StockPicksNYC) April 28, 2025
•$5M market cap
•$32M revenue across Feb-March
•$62M in Assets (10-K)
•Audit underway
•Big name clients including AT&T $T, Verizon $VZ
•Acquisitions, evaluating targets
•Share buyback
•NYSE Floor interview 4/30
•Multiple analyst reports issued… https://t.co/gY5Q2txkW6 pic.twitter.com/8wgRFsYfcm
VTXB is on GIANT FIRE today with 400M shares of Huge Slapping volumes! Ready to create A Series Of New 52-Week-Highs above its current Ridiculous-Low 52-Week-High $0.0006! The Low AS is the FIXED 4B shares while the Low OS is the FIXED 3.7B shares! NEVER R/S in its Entire public trading history except Once 10:1 F/S back to 02/09/2007! Frequently Paying Cash Dividends to all its common shares! It will be Very Easy for this Hidden Gem to Quickly Surge Over its most recent high $0.0013 in the coming days based on its 1.6B shares Low float and Red-Hot Bitcoin-Mining business etc....
VTXB is Super Undervalued now based on its peer's Market Value and Recent Performance! Also at Hyper Oversold status --- from its recent highs area $0.0951 ~ $0.0050 to its Bottom $0.0001!
Note, total 100,000 shares are Shorted based on the Latest public Information. the FULLY-Reporting Current-Information-tier VTXB is Much-Much-Much Cheaper than BIEL, VIZC, CGAC, BLDV, ALST, LVGI, EPAZ, GRCU, AURI, RDAR, and TRSI etc. OTC peers!
MULN had bounced up over 87.5% from $0.7999 (04/21/25's afterhours-low) to $1.5 (04/22/25's premarket-high)!
The Bitcoin-Mining Hidden Gem (VTXB) has already Bottomed out at 0.0001 and Bounced Up 100% so far! Easy to Quickly surge over its most recent high 0.0050!
The Bio-Tech Hidden Gem (VINC) is Much-Much-Much Cheaper than PRSO now!
Watch these TWOH RDAR VGTL RHCO BNCM AHRO
Also look into PRSO it’s been starting to move. DD video out on YouTube today
RDAR... NEWS NEWS.... Up 27.27% and still at .0007.. this is a must own stock...
EQS-News: Raadr Inc., Doing Business as Telvantis, Selected for an Interview on the Floor of the NYSE Press Release | 04/23/2025
EQS-News: Raadr Inc., Doing Business as Telvantis, Accelerates With $32M+ in Revenue Across February and March; Business Plan Relaunch Gaining Momentum Press Release | 04/21/2025
EQS-News: Raadr, Doing Business as Telvantis, Transitions From Restructuring to Execution; Launches Phase 2 of Growth PlanPress Release | 04/10/2025
EQS-News: Raadr Inc., Doing Business as Telvantis, Completes Final Stage of Legacy Debt Remediation, Paving the Way for New Growth Phase Press Release | 04/01/2025
Heads up on RHCO $5.7M in revenue last quarter and net profitable. Only 24M shares held at DTC. New play I’m going to be posting a lot of DD on them
$RHCO News out today! Going to post some DD on this gem tomorrow
— Stock Picks NYC (@StockPicksNYC) April 21, 2025
•$5.7M in revenue last quarter Q4
•Net profitable
•$12.9M in assets
•No convertible notes
•Small float, 24M held at DTC pic.twitter.com/gGumzSuWIV
VTXB is ready to create A Series Of New 52-Week-Highs above current joke low 52-Week-High $0.0006! The Low AS is the FIXED 4B shares while the Low OS is the FIXED 3.7B shares! NEVER R/S in its Entire public trading history except Once 10:1 F/S back to 02/09/2007! Frequently Paying Cash Dividends to all its common stock! It will be Very Easy for this Hidden Gem to Quickly Surge Over its most recent high $0.0013 in the coming days based on its 1.6B shares Low float and Red-Hot business model --- Bitcoin mining...
VTXB is Super Undervalued now! Also at Hyper Oversold status --- from its recent highs area $0.0951 ~ $0.0050 to current Bottom $0.0001!
Note, total 100,000 shares are Shorted based on the Latest public Information. VTXB is Much-Much-Much Cheaper than IVDN, BLDV, ALST, LVGI, EPAZ, GRCU, AURI, and TRSI etc.!
$IVDN Feature: $1 Million Milestone & Continued Profitability Projected for First Half of 2025 with Accelerating Sales for Key Supplier in Multi-Billion Homebuilding Industry: Innovative Designs, Inc. (Symbol: IVDN)
By: Get News
April 07, 2025 at 16:46 PM EDT
https://markets.financialcontent.com/streetinsider/article/getnews-2025-4-7-1-million-milestone-and-continued-profitability-projected-for-first-half-of-2025-with-accelerating-sales-for-key-supplier-in-multi-billion-homebuilding-industry-innovative-designs-inc-symbol-ivdn/
From the article:
$IVDN New Board Member for Superior Insulation Maker has Ties to Industry Leaders Including D.R. Horton $DHI, Ryan Homes $NVR and More / Super Small Share Structure with Only 38 Million OS / 16 Million Float
Sole Maker of Patented Insultex® Insulation Delivering Construction Cost and Energy Saving Performance Superior to All Competition.
Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.
Over $1 Million in Revenue with Profitability Projected in the First Half of 2025.
Fiscal First Quarter Results Deliver Over a 720% Increase, Largest Percentage Revenue Growth in Company History.
Profitability Reached for First Time at Fiscal 2024 Year-End on Almost 300% Revenue Increase vs. Previous Year.
New Government Building Codes Require Continuous Insulation with Higher Performance. IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.
Increased Order Fulfilment Capabilities with Plans for Further Enhancement to Handle Strongly Increasing Demand.
Process Underway for Uplisting to OTCQB Tier.
New Board Member is Experienced Real Estate Developer with Relations to Top Homebuilding Names Including D.R. Horton, NVR / Ryan Homes and More.
LVGI is Up 100% from its New Bottom $0.0002! Easy to test its 52-week-high $0.0006 again!
VTXB (Sought-After Current-Information-tier) is Much-Much-Much Cheaper than LVGI (Risky Limited-information-tier) now! Easy to surge over its 52-week-high $0.0007...
Note, LVGI might file the CH7 Liquidation BANKRUPTCY very soon due to its HUGE NEGATIVE Net Asset --- $6M HUGE DEBTS vs. VTXB only has -$0.3M MINOR Net Asset!
LVGI has -$0.0082 a share HUGE NEGATIVE Book Value vs. VTXB has -$0.0001 a share MINOR Book Value!
VTXB is at Hyper Oversold status --- from its recent high 0.0951 to current Bottom price 0.0001!
VTXB is Much-Much-Much Cheaper than AHRO!
TWOH and AHRO steadily climbing DD thread on both below
AHRO:
$AHRO Here’s a quick video on WhaleTV, a giant smartTV “OS” powering over 41M+ active SmartTVs
— Stock Picks NYC (@StockPicksNYC) April 3, 2025
AHRO’s iDreamCTV & WhaleTV partnership going live this month (April)
iDreamCTV is a smart TV streaming app, similar business model as TUBI, HULU, $NFLX, $FUBO, $PARA, $DIS, PlutoTV… https://t.co/3lCI7Hjex3 pic.twitter.com/IZW0cGmLCE
$TWOH Hitting new highs!🔥
— Stock Picks NYC (@StockPicksNYC) April 3, 2025
•Change of control, Emil Assentato, former CEO of NASDAQ: $NUKK
•Craig Marshak added to board of directors
•Incoming acquisitions/merger
•No reverse split confirmed in recent PR and 8-K
•54% of outstanding shares owned by CEO Emil Assentato… https://t.co/moF4OwM8j9 pic.twitter.com/EyP75uTn5S
ASII... .0004 stock is ready for take-off... Finally great NEWS https://www.otcmarkets.com/stock/ASII/news/story?e&id=3196475
AURI (7.4B/10B shares High OS/AS) has Bottomed-Out at a Much-Much-Much-Higher New Supporting price $0.0001, instead of its Real Bottom $0.000001! Oversold status! We might see a Quick Bounce to January's high $0.0003 again in the coming days...
Anyway, its Red-Hot Bitcoin-Mining Hidden Gem (VTXB: 3.7B/4B shares Low OS/AS) could Easily and Rapidly surge back to its recent highs area $0.0050 ~ $0.0951 again because VTXB (at the Cheapest Bottom $0.0001 now) is a Much-Much-Much-Better Investment-Grade NEVER-R/S Frequently-Paying-Cash-Dividend Super-Undervalued Hyper-Oversold Fully-Reporting Much-Much-Much-Lower-SS Current-Information-tier OTC stock than AURI! Which one is cheaper --- CYCU or VINC?
$CYCU: Cycurion CEO Kevin Kelly Provides Corporate Update in Letter to Stockholders
MCLEAN, Va., March 18, 2025 (GLOBE NEWSWIRE) -- Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, provides a corporate update in a Letter to Stockholders from CEO Kevin Kelly:
Dear Fellow Stockholders,
After a volatile first month of trading following Cycurion’s entrance into the Nasdaq market, I want to reiterate the Cycurion team’s and my commitment to our stockholders. We remain highly confident in achieving our objectives that will ultimately drive intrinsic enterprise value growth underpinned by three key levers:
Expansion of our groundbreaking AI-powered ARx Security Platform, which we believe has the potential to revolutionize the cybersecurity market and serve as a game-changer for Cycurion with its high SaaS margin profile.
Organic companywide growth, including expanding current client relationships where there is tremendous opportunity for growth, primarily in the ARx vertical, driven by a focused strategy that includes sales & marketing talent additions.
Opportunistic and accretive acquisition strategy that seeks complementary additions to Cycurion’s existing offerings, while expanding sales reach. This strategy offers selling enterprise/government cybersecurity and IT support firms a value realization opportunity with a growing, trustworthy successor.
ARx Security Platform – Significant Organic, High-Margin AI-Powered Cybersecurity Growth Platform. At the heart of our growth strategy is the recently announced ARx Security Platform, an unrivaled cybersecurity innovation with the potential to disrupt the existing cybersecurity landscape. Powered by advanced AI technology, this robust solution provides real-time insights and protection against evolving cybersecurity threats. ARx offers a comprehensive multi-layered defense mechanism that includes a Web Application Firewall, Bot Mitigation, and Geo Gating. Additionally, as a pure SaaS offering, ARx can be deployed in a rapid and seamless manner without cumbersome and costly network hardware installations.
With high product margins, the ARx Security Platform is both a cybersecurity industry breakthrough and the foundational future contributor to Cycurion’s growth. We are laser-focused on expanding this high-margin & ROI segment to drive sustained growth and establish a formidable position in the cybersecurity space. We strongly believe ARx’s value proposition will ultimately be positively reflected in the price of Cycurion stock upon the market both obtaining a better understanding of the offering’s worth and making the connection for all stakeholders that Cycurion is now a leading cybersecurity provider. We look forward to sharing more details on our vision for ARx and its growth over the coming months.
Our Team. Cycurion’s success has always been built on the expertise and dedication of our world-class team of cybersecurity professionals. We have 70 great employees, many possessing the highest level of government security clearance, working at the upper echelon of government and corporate organizations, ensuring superior client service and driving our growth.
Accretive Acquisitions for Enhanced Capabilities. Cycurion will also seek growth with an opportunistic lens via highly strategic, complementary acquisitions that are designed to enhance our capabilities and extend our reach in both the government and commercial sectors. These prospective acquisitions will be designed to strengthen our technology portfolio, expand our client base, and accelerate our growth. By complementing our cutting-edge ARx Platform with these prospective strategic additions, we intend to reinforce Cycurion’s leadership in cybersecurity innovation and ensure Cycurion is well-equipped to meet the demands of a rapidly changing market.
Capital Structure Update
Current outstanding number of shares of common stock is just over 30 million, which yields a basic market capitalization of $16.2 million, based on the closing share price on March 17 of $0.54; and
If all the of outstanding shares of the various series of preferred stock are converted and all of the outstanding warrants are exercised for shares of common stock, the pro forma total number of shares of then-outstanding common stock would be approximately 46 million (excludes the pre-existing SPAC warrants that are significantly out-of-the-money, exercisable at $11.50/share); and
The total potential capital that Cycurion could receive from the exercise of all of the warrants that remain outstanding (excluding the $11.50 SPAC warrants) would be approximately $4.0 million.
Conclusion. We believe we have a highly valuable solution in our ARx Security Platform. We are enthusiastic about executing our growth strategies as we strive to deliver lasting value to our stockholders. We are confident in accomplishing the task at hand and will seek to buttress our stance by adding talented individuals who are aligned with our core beliefs and driven to succeed. We believe that Cycurion is optimally positioned to capitalize on the rapidly growing global demand for cybersecurity solutions with cybercrime costs projected to reach $10.5 trillion annually, and the cybersecurity market nearing $200 billion.
Moreover, we are mindful of the heightened volatility in the price of Cycurion’s stock over the recent weeks. The challenging broader market, and the technology sector in particular, has been under significant pressure since the middle of February, coincidentally when we completed the transaction that brought Cycurion public. That said, please rest assured that all of us, Alvin McCoy (CFO), the Board of Directors, the entire integrated Cycurion team, and I are working with the singular mission to execute our model and drive increasing value for Cycurion stockholders. We thank you for your initial support, and we look forward to sharing additional positive news with you in the near future.
Sincerely,
Kevin Kelly
Cycurion CEO
About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.
Forward looking Statements
This letter to our stockholders and press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Investor Contact:
CORE IR
investors@cycurion.com
Media Contact:
Phone: (703) 555-0123
Email: media@cycurion.com
TRSI is bouncing up 89.5% so far from its New Bottom $0.0038 due to its "Oversold" status! It can hit the Penny Land as soon as tomorrow!
The most recent high $0.019 should be tested again in the coming days...
Its OTC-CI-tier peer (VTXB) is a Much-Much-Much-Better Investment-Grade NEVER-R/S Super-Undervalued Hyper-Oversold Bitcoin-Mining Red-Hot stock with Frequently-Paying-Cash-Dividends! At GIANT-Discount Bottom $0.0001 now! Easy to Quickly surge back to $0.0955 ~ $0.0050 price area again!
ASII..... This is the the one you need to own......HUGE news https://www.otcmarkets.com/stock/ASII/news/story?e&id=3165818
$CYCU News: Cycurion (Nasdaq: CYCU) Awarded Three Multi-Year Contracts Highlighting Growth and Innovation
MCLEAN, Va., March 05, 2025 (GLOBE NEWSWIRE) -- Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces the award of three new multi-year contracts focused on program management, cybersecurity, and disaster recovery/business continuity. These engagements—secured with two government clients and one commercial client—reflect the Company’s ongoing commitment to delivering exceptional services and expanding its reach.
These contracts, which represent a total of up to $6 million in revenue over six years, mark a significant step forward for Cycurion, highlighting its ability to serve both government and commercial sectors while strengthening its international client footprint. The Company’s ARx platform, enriched with AI-driven tools and IT cybersecurity solutions, provides a robust foundation for addressing complex challenges and delivering tailored, forward-thinking results.
“These awards are also a testament to the hard work and dedication of our team,” added Kevin Kelly. “We’re enthusiastic about the opportunities ahead and remain focused on growing our capabilities to meet the evolving needs of our clients. We believe this is an exciting time for Cycurion, and we look forward to providing significant value for all of our stakeholders.”
Cycurion will continue to provide updates on its progress and innovations as it continues to build on its mission of excellence in IT cybersecurity solutions and AI.
About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients with a commitment to securing the digital future.
Forward looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Investor Contact:
CORE IR
investors@cycurion.com
Media Contact:
Phone: (703) 555-0123
Email: media@cycurion.com
https://www.globenewswire.com/newsroom/ti?nf=OTM4OTIwMyM2NzkxMjk3IzIyOTg5MDA=
https://ml.globenewswire.com/media/OWI1ODY3NTAtMGE1Mi00ZTAzLWIyMGYtNDE4ZjE3YTAxYjBmLTEzMTA0NTA=/tiny/Cycurion.png Source: Cycurion
ADHC files Breakthrough Device application with FDA for their diabetes medical device. Crazy to see this at a 1M market cap, especially with a pending FDA application
Also they have a former FDA official Stephen Weber who’s on their advisory board that led the team through the application. He knows exactly what the FDA looks for before approving an application
Here’s a DD thread on the company
$ADHC GlucoGuard Files Breakthrough Device Application with the (FDA) US Food and Drug Administration!👀https://t.co/jt0r0NIgsi
— Stock Picks NYC (@StockPicksNYC) March 5, 2025
Crazy to see $ADHC at a 1M market cap, especially with a pending FDA application$MVCO $RDGL $IGEX $CAFL $ADIA $MRES $RDAR $VDRM $TTOO $ORGS $HMBL https://t.co/wAboSk9XyS pic.twitter.com/efl6aGWBZd
$CYCU News: Cycurion Announces U.S. Launch of its AI Driven SaaS ARx Platform Targeted to the Corporate Sector
New high margin, AI-driven cybersecurity solution expands Company’s reach following strong initial reception in the government and public sectors
MCLEAN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Cycurion (NASDAQ: CYCU), a pioneer in advanced cybersecurity solutions, today announces the availability of its ARx Platform targeted for the corporate sector. Having been extensively tested and successfully implemented in both the government and public sectors, this comprehensive, AI-powered platform has proven its versatility, delivering cutting-edge security to an expanding array of clients, from federal agencies to Fortune 500 enterprises.
The ARx Platform has solidified its reputation with key government bodies, including the U.S. Department of Justice (DOJ), the Department of Defense (DOD), and numerous state and local governments, while also gaining traction in the public sector. On February 24, 2025, Cycurion announced a landmark 24-36-month partnership with a national public health association, extending ARx to thousands of healthcare organizations nationwide.
Building on the momentum with government and public sector clients, Cycurion has now launched the ARx Platform into the corporate sector, where, to date, it has been met with an equally warm reception. Targeting industries such as finance, retail, and technology, the platform’s scalability and robust feature set have resonated with corporate leaders seeking to protect their digital assets amid rising cyber threats. Notably, this expansion reflects the platform’s high demand and operational efficiency while yielding a highly attractive ~80% gross profit margin.
Developed over four years with significant investment, the ARx Platform integrates a Web Application Firewall (WAF), DDoS protection, bot mitigation, geo-gating, and endpoint security, all powered by proprietary AI and machine learning algorithms. This multilayered approach ensures real-time threat detection and automated responses with minimal false positives, addressing compliance, staffing shortages, and escalating risks. Its SaaS model and flexible pricing have made it accessible to organizations of all sizes.
“The corporate sector has embraced ARx for its ability to deliver enterprise-grade security in a pure SaaS model, absent a cumbersome network appliance, ultimately delivering unmatched ROI,” said Kevin Kelly, Chairman and CEO of Cycurion. “ARx both meets the critical needs of global enterprises of all sizes and complexities while generating tremendous value for Cycurion shareholders with its ~80% margin profile. Further, the strong reception across all sectors—government, public, and corporate—shows ARx is a universal solution. From the DOJ and DOD to state governments and now leading corporations, we’re bridging the cybersecurity gap with innovation and reliability.”
With cybercrime costs projected to reach $10.5 trillion annually, and the cybersecurity market nearing $200 billion, Cycurion’s ARx Platform is optimally positioned as a multi-sector cybersecurity leader.
For more information about the ARx Platform, visit www.cycurion.com or contact media@cycurion.com.
About Cycurion
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) provides state-of-the-art cybersecurity through its AI-powered ARx Platform and subsidiaries Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc. Serving government, healthcare, and corporate clients, Cycurion is committed to securing the digital future.
Forward looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.
Many factors could cause Cycurion’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-4, as filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in that filing with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Investor Contact:
CORE IR
investors@cycurion.com
Media Contact:
Phone: (703) 555-0123
Email: media@cycurion.com
https://www.globenewswire.com/newsroom/ti?nf=OTM4ODQxMiM2Nzg5MTEzIzIyOTg5MDA=
https://ml.globenewswire.com/media/MGVkM2RmYWQtYjUyZC00YjU1LWFmMTAtN2U4ZWI0MTcxMTAxLTEzMTA0NTA=/tiny/Cycurion.png Source: Cycurion
BNCM massive merger, gotta see this
$BNCM Here’s another video of Delex Pharma showing how big the company really is
— Stock Picks NYC (@StockPicksNYC) February 20, 2025
One of the biggest mergers in the OTC!
Latest PR mentions the management transfer is set to be completed by March 2025$AIBT $CAFI $RITE $STRH $RDAR $IGPK $RDGL $HIRU $IGEX $NBRI $GTII $ADIA $SPZI https://t.co/DqaKdDEAPe pic.twitter.com/YHzi9YPUbb
EPAZD will run as soon as next week due to Extremely Oversold status after 1:2500 Giant R/S! We might see a Short Bouncing to its most recent high $1.75 again.
Anyway, the Red-Hot Super-Undervalued & Hyper-Oversold & NONE-R/S-History Bitcoin-Mining Hidden Gem (VTXB) could Easily And Quickly surge 600-Bagger ~ 50-Bagger to hit its recent highs area $0.06 ~ $0.0050 again...
TTOO (previous NASDAQ Bio-Tech stock before 02/12/2025) will run soon to fill up its most recent Huge Gap once it is Bottomed-Out! At Hyper Oversold status! We might see a crazy Bouncing Rally up to $0.2xxx in the coming days/weeks...
Anyway, its NASDAQ Bio-Tech peer (VINC: $5.43 a share Huge POSITIVE Book Value and $1.76 a share High Positive Cash Value) has 10-Bagger Huge Rally potential as soon as this month! The Red-Hot Bitcoin-Mining Hidden Gem (VTXB) could Easily surge back to its recent highs area $0.06 ~ $0.0050 again...
VTXB is trading at $353K Low MV at Bottom $0.0001 vs. AIBT has $1097K or $1.1M High MV at $0.026!
ASII ... AMOD CEO and founder is William Alessi. Alessi was the CEO and CFO of ASII.... Could this be the connection and possible merger we are hearing about from the CEO that said something big will be announced next week? ASII is at .0005 and going fast.
AIBT market cap $1M acquiring $40M company
$AIBT I like this one. Acquiring https://t.co/IpqQ6UyS1p in a $40M transaction
— Stock Picks NYC (@StockPicksNYC) February 12, 2025
•1M Market cap
•Only 4.9M shares held at DTC
•FINRA approved ticker change, formerly $TPIA
Digitrax:
•$32M valuation their last funding round
•Part of the $NVDA inception and $INTC AI partner… https://t.co/YPALAg2m4Y pic.twitter.com/SVLPi45kZE
$ACGX News: Alliance Creative Group ($ACGX) Reports Sale of Chicago Property with Financial Gains; New Investments Now Being Sought
February 10, 2025
News Link:
https://www.einpresswire.com/article/784083279/alliance-creative-group-acgx-reports-sale-of-chicago-property-with-financial-gains-new-investments-now-being-sought
$ACGX is pleased to announce the Company’s real estate property located at 6403 N. Wayne Ave Chicago, IL has been successfully sold for $3,450,000.
CHICAGO, IL, UNITED STATES, February 10, 2025 /EINPresswire.com/ -- Alliance Creative Group, Inc., (ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the Company’s real estate property located at 6403 N. Wayne Ave & 1324 W. Devon Ave, Chicago, IL has been successfully sold for $3,450,000. This sale now represents a reduction of $3,311,552 in Liabilities from the 9/30/24 Balance Sheet along with $264,243 in cash deposited in the ACGX bank account.
ACGX is now searching to find additional investment opportunities with the net cash proceeds and improved balance sheet from the Chicago property sale to help increase our overall shareholder value. Ideally, we are seeking to acquire majority control of a positive cashflow subscription software or services business to help scale and grow. Our target objective is for an acquisition in the $1 million to $5 million revenue range that has potential for exponential growth.
Our full financial statements, balance sheets, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX.us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "We are excited to have completed the sale of our Chicago real estate property. With the multiple benefits that this sale has delivered to ACGX we are now in a very favorable position to progress on to our next investment opportunities. We are currently reviewing some options but we certainly welcome all assistance from any parties in identifying new investments that would meet our criteria, particularly in the software or services business.”
The Company’s shares of www.PeopleVine.com continue to be a very rewarding investment for ACGX and the conversations with the growth capital investment groups have been quite beneficial. Our goal is to convert between 20% to 30% of the PeopleVine investment into cash in 2025 so we can use a lot of it to invest in future projects while we let the majority of the shares hopefully continue to increase in value.
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit www.AllianceCreativeGroup.com or http://www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SAAS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information http://www.PeopleVine.com
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Relations and Media Contact
info@ACGemail.com
SOURCE Alliance Creative Group, Inc.
Paul Sorkin
Alliance Creative Group, Inc.
paul@acgemail.com
VTXB just created a New 52-week-low $0.0001 on January 17, 2025! The AS is 4B or 4,000,000,000 shares while the OS was just diluted to 3,287,750,000 shares (on January 21) from January 20's 3,037,750,000 shares! Once the current dilution is done it may surge over last-January's high $0.0011 very easily based on its Low float (1.6B shares) and Hot business model (Bitcoin mining)...
The 52-week-high is $0.0011!
VINC was Up 8.494% or has bounced Up 8.961% yesterday! It seems already Bottomed Out at the New 52-week-low $0.1395!
It is Extremely Undervalued now based on its Positive Book Value $0.27143 per share!
It is also at Extremely Oversold status based on its most recent high $0.52 on 12/30/2024!
Easy to Quickly hit $0.4 again Within just A Single Day based on its Small Trading Volumes since 12/31/2024!
$FAVO News December 12, 2024
FAVO Capital, Inc Closes $2 Million Bridge Raise Led by D. Boral Capital
https://finance.yahoo.com/news/favo-capital-inc-closes-2-133000547.html
$GPOX News: GPOPlus+ Announces Warehouse Upgrades and Cash and Carry Model Expanding Retail Reach
Upgrading Warehouses to Ambient Temperature Control Enables Expanded Product Lines and Cash and Carry Model Enhances Service Efficiency While Opening New Revenue Channels
LAS VEGAS, NEVADA / ACCESSWIRE / December 18, 2024 / GPO Plus, Inc.(OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative AI-driven Direct Store Delivery (DSD) model, is pleased to announce plans to significantly increase its product offering by upgrading its warehouse network of Regional Hubs and Mini Hubs to ambient temperature control and cooling. The Company will also use this opportunity to integrate a Cash and Carry model into the warehouse network.
GPOX Cash and Carry
Strategic Growth and Operational Efficiency Highlights
Add new high-demand product categories to its distribution network.
Expand services to include retailers such as smoke shops, vape shops, and liquor stores.
Leverage existing infrastructure to increase sales channels, driving additional revenue streams.
Upgrading Regional Hubs and Mini Hubs to ambient temperature-controlled facilities enables the storage and distribution of new product categories, such as snacks, general merchandise, and other in-demand products. This allows us to significantly increase sales per store in our existing retail network. Integrating the Cash and Carry model allows retail customers to either pick up products directly from GPOX facilities or order them for drop shipment or delivery. This dual functionality expands both GPOX's product offerings and retail reach, creating new opportunities to serve retail partners that may not require full DSD service.
"Over the last year, we've refined our DSD model, significantly improving operational efficiencies," said Brett H. Pojunis, CEO of GPOX. "Now, we're focusing on scaling revenues by opening new sales channels. Taking advantage of this upgrade to our warehouses allows us to expand both our product lines and retail network, leveraging our existing assets to enhance reach and efficiency in the markets we already serve. These initiatives position GPOX for sustained growth while maintaining our commitment to operational excellence."
To learn more, visit GPOPlus.com.
Connect with us on social media to view live video updates, content, and general information about GPOX: https://gpoplus.com/social.
About GPOPlus+ (GPOX)
GPOX is an AI-powered Distributor revolutionizing the future of distribution to gas stations and convenience stores with its innovative AI-driven Direct Store Delivery (DSD) model. Our goal is clear and ambitious: "to build the largest nationwide DSD distribution company servicing gas stations, convenience stores, and beyond." Our technology-driven AI network, featuring strategically placed Regional Hubs and Mini Hubs, is designed to optimize efficiency and maximize reach. Central to our operations is our in-house AI technology platform, PRISM+. Designed to streamline the distribution process, PRISM+ supports efficient delivery, inventory management, data analytics, and overall operational excellence, enabling us to reliably and effectively meet the dynamic needs of our partners. Our mission is to consolidate the fragmented market segment managed by numerous regional vendors. Our dedication to excellence is evident in our product selection process, where we align offerings with consumer demand and partner with top-tier vendors and brands, ensuring our portfolio remains diverse and highly profitable.
For more information, please visit www.GPOPlus.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company's need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company's products, and other risks that are detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as "may," "will," "can" "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company's actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Company Contacts:
GPOX Shareholder Success Team:
Brett H. Pojunis, CEO
Email: ir@gpoplus.com
Shareholder's Line: 855.935.GPOX (4769)
SOURCE: GPO Plus, Inc.
$CBDW Update from X: Explore the most recent blog from 1606. Explore the most recent blog from 1606.https://t.co/vxmzw5lyKA
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit http://www.cbdw.ai
$CBDW News: 1606 Corp. AI Chatbots Innovations, Highlights Adnexus LOI, and Quarterly Reporting Update After Q3 Filling
SEATTLE, WA / ACCESSWIRE / November 19, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company," or "1606") has made strong progress in the latest quarter, positioning itself as a key player in the growing AI chatbot market. The Company has focused on expanding its product offerings, forging strategic partnerships, and investing in innovative AI technology that enhances user interactions across industries. A key milestone for the Q3 includes strategic partnerships with Adnexus, marking a significant leap in the Company's AI-driven solutions.
Key Developments:
Quarterly SEC reporting:
We are excited to announce that we have filed our 10-Q for the quarter ended September 30, 2024. This filing reflects our commitment to transparency and regulatory compliance, providing investors and shareholders with detailed insights into our financial performance and operational activities. We are proud that we have been able to stay current with all fillings since our inception three years ago.
Expansion of Market Reach:
Throughout the quarter, we made substantial efforts to increase our market reach into the rapidly growing demand for AI-driven customer service and automation tools. We are committed to exploring new opportunities for expansion, particularly in sectors such as e-commerce, finance, healthcare, and telecommunications, where AI-powered chatbots are increasingly in demand. We have already created two chatbots that can be tested at cbdw.ai
Ongoing AI Innovation and Product Development:
Innovation remains at the core of our strategy, with a continuous focus on improving our AI chatbot capabilities. By integrating more advanced machine learning models and NLP techniques, we aim to provide highly personalized, human-like interactions for businesses and consumers alike.
Strategic Partnership with Adnexus Biotechnologies:
We signed a Letter of Intent (LOI) with Adnexus Biotechnologies, a leading firm in AI and biotechnology solutions. This potential strategic investment underscores our commitment to expanding our technological footprint and enhancing our capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster our portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
CEO Statement
Austen Lambrecht, CEO of 1606 Corp., commented, "This has been a transformative quarter for 1606 Corp. With the successful filing of our third consecutive Quarterly Report, we continue to demonstrate our commitment to transparency and regulatory compliance. A key milestone for Q3 was the signing of our Letter of Intent with Adnexus Biotechnologies, which opens exciting new opportunities in the AI sector." Lambrechht continued, "We're building a strong foundation for long-term growth by expanding our technological capabilities and forging strategic partnerships. I'm incredibly proud of our team's progress and look forward to further advancing our mission of innovation and excellence in the months ahead."
Outlook for the Next Quarter:
Looking ahead, 1606 Corp's focus will be on:
Closing Strategic Investment with Adnexus: We will be focused on closing the investment in Adnexus Biotechnologies.
Expanding AI Chatbot Solutions: We will continue to enhance our AI capabilities, with plans to launch additional AI-powered chatbot solutions that offer businesses even more advanced tools for automation, customer service, and engagement.
Growing Market Presence: Through the partnership with Adnexus, we aim to expand our reach into new verticals, such as healthcare, finance, and telecommunications, where AI chatbots are rapidly becoming essential for operational efficiency.
Increased Revenue from AI Chatbots: As AI solutions like Chat IR gain traction, we expect to see a rise in demand for our products, which we believe will contribute to revenue growth in the next quarter.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit http://www.cbdw.ai.
Industry Information
The global AI market, valued at $428 billion in 2022, is anticipated to reach $2.25 trillion by 2030, with a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%. The sector is expected to employ 97 million individuals by 2025, reflecting its expansive and significant impact. This potential growth presents a compelling opportunity for investors and industry professionals interested in the AI sector.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. The Company does not undertake any obligation to update forward-looking statements except as required by law.
Contact Information
Austen Lambrecht
CEO
austen@1606corp.com
SOURCE: 1606 Corp
$MRPT - The Premier Digital Asset Management Platform.
MacReport offers investors the opportunities to diversify and include digital assets in their portfolios. We work with only those cryptocurrencies and tokens that are not deemed to be securities by the Securities Exchange Commission. We leverage years of experience in trading and regulatory compliance to provide institutional grade service with safety in mind.
http://www.themacreport.net/
$BLIS has issued 4 extremely positive announcements recently. These include a signed LOI on a major $370 Million defense contract in the Middle East (See Oct. 22nd news below).
Oct. 29, 2024: NAPC Defense and Lamperd Less Lethal form Partnership for Security Products Marketing in The USA and Worldwide
https://www.morningstar.com/news/globe-newswire/9263212/napc-defense-and-lamperd-less-lethal-form-partnership-for-security-products-marketing-in-the-usa-and-worldwide
Oct. 25, 2024: NAPC Defense (OTCPK: BLIS) to Demonstrate Corner Shot and Attend SWAT Round-Up 2024 as a Convention Exhibitor
The Company Plans to Meet with leading SWAT Team Members, Law Enforcement Officers, Military Personnel, and other Industry Experts
https://www.globenewswire.com/en/news-release/2024/10/25/2969429/0/en/NAPC-Defense-OTCPK-BLIS-to-Demonstrate-Corner-Shot-and-Attend-SWAT-Round-Up-2024-as-a-Convention-Exhibitor.html
Oct. 24, 2024: NAPC Defense (OTCPK: BLIS) Awarded in Excess of $1 Million in Clean-up Contracts following Hurricanes Helene and Milton
The Company is Working on Additional Potential Restoration and Clean-up Contracts
https://finance.yahoo.com/news/napc-defense-otcpk-blis-awarded-120500313.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
Oct. 22, 2024: NAPC Defense, Inc. (OTCPK: BLIS) issues Progress Report regarding Large Contract with Saudi Arabia
https://www.globenewswire.com/news-release/2024/10/22/2966948/0/en/NAPC-Defense-Inc-OTCPK-BLIS-issues-Progress-Report-regarding-Large-Contract-with-Saudi-Arabia.html
$CBDW News: 1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of Adnexus's HIV and SARS-CoV-2 research.
Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.
The acquisition further strengthens Adnexus's position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, Adnexus is uniquely positioned to accelerate the development of high-impact therapies.
Austen Lambrecht, CEO of 1606 Corp., commented, "The merger between Adnexus Biotechnologies and Sanctum Therapeutics marks a pivotal moment in the fight against HIV and other infectious diseases. By combining Adnexus's cutting-edge AI-driven drug discovery platform with Sanctum's breakthrough therapies, they are not only advancing the development of life-saving treatments but also driving forward our mission to leverage technological innovation for the betterment of global healthcare. Lambrecht continued, "This strategic partnership underscores our commitment to supporting transformative biotech advancements, and we are excited to play a role in helping bring these therapies to market for those who need them most."
This synergistic combination of resources, along with Adnexus's cutting-edge Sutra AI Drug Discovery Platform, creates a powerful foundation for continued innovation and growth, ultimately delivering significant value for patients and shareholders alike.
Adnexus has recently executed a Letter of Intent with the Company for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.
About Adnexus Biotechnologies Inc.
Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit cbdw.ai
Industry Information
The global AI market, valued at $428 billion in 2022, is anticipated to reach $2.25 trillion by 2030, with a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%. The sector is expected to employ 97 million individuals by 2025, reflecting its expansive and significant impact. This potential growth presents a compelling opportunity for investors and industry professionals interested in the AI sector.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. The Company does not undertake any obligation to update forward-looking statements except as required by law.
For inquiries, please contact our CEO, Austen Lambrecht, at austen@1606corp.com.
Contact Information:
Austen Lambrecht
CEO
austen@1606corp.com
SOURCE: 1606 Corp.
$MRPT Share Structure
Authorized Shares 25,000,000 11/12/2024
Outstanding Shares 17,960,633 11/12/2024
Restricted 16,146,861 11/12/2024
Unrestricted 1,813,772 11/12/2024
https://www.otcmarkets.com/stock/MRPT/security
$CBDW: Adnexus Biotechnologies Unveils Sutra(TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research
DALLAS, TX / ACCESSWIRE / October 1, 2024 / Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research, is pleased to announce its new AI Empowered Drug Discovery Platform, Sutra™.
https://www.accesswire.com/imagelibrary/0ba2a55f-87c0-4f57-b991-9a3a312c6109/925182/12084.png
The Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. Adnexus Biotechnologies Inc.'s AI algorithms have identified several promising drug candidates. The company has identified a target in the mitochondrial metabolism that has a role in oncology. The company then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.
Adnexus Biotechnologies Inc. is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With its AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules. With a database of 19 viruses, the Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The Sutra™ team's unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.
Adnexus Biotechnologies Inc. harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. Adnexus is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.
Gaurav Chandra, the CEO of Adnexus Biotechnologies Inc., stated, "Our innovative use of AI reflects a broader trend toward embracing advanced technologies to overcome traditional limitations in the biotech industry. We are very excited about our AI-empowered drug discoveries. Adnexus is proud to introduce and implement the latest Artificial Intelligence innovations in research and development technology-keeping the company at the forefront of early drug discovery and development and other revolutionary discoveries critical to treating infectious diseases."
Dr. Chandra continued, "As we advance our HIV therapeutics, we intend to offer our expertise as unique SAAS and DAAS revenue-generating models by next year. This strategic move is part of our commitment to pursuing multiple revenue-generating strategies to broaden our offerings and support academic and biotechnology companies in advancing their scientific endeavors. This commitment underscores our financial stability and growth potential."
Adnexus has recently executed a Letter of Intent with 1606 Corp (OTC PINK:CBDW), an AI technology company, for a strategic investment in the company.
About Adnexus Biotechnologies Inc.
Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.
Industry Information
The global market size for artificial intelligence in drug discovery was estimated at USD 1.5 billion in 2023 and is projected to grow at a CAGR of 29.7% from 2024 to 2030. The demand for AI-powered solutions in drug discovery is increasing due to the need for new drug therapies, expanded manufacturing capacities in the life sciences industry, and technological advancements. AI technologies such as machine learning and deep learning are being used at various stages of drug discovery, including initial compound screening and predicting success rates in clinical trials. Additionally, the growth of startups developing AI-powered solutions and increased investments and funding drive market expansion.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. Adnexus does not undertake any obligation to update forward-looking statements except as required by law.
For inquiries, please get in touch with Dr. Gaurav Chandra, CEO, gaurav.chandra@adnexusbiotech.com.
https://www.adnexusbiotech.com
http://www.cbdw.ai
Contact Information
Gaurav Chandra
CEO
gaurav.chandra@adnexusbiotech.com
SOURCE: Adnexus Biotechnologies Inc.
$ASII reached agreement with all convertible parties for a 60 day lock up and 6 month leak out on all conversions.. This is about to be another "think like the crooks" moment coming up. They can't convert so they'll push this upwards and have it higher for when they can!
KXIN (NASDAQ-Exchange stock) is at Hyper Oversold status now --- from May 17's pre-market high $0.6 to last Friday's daily low $0.0745 which is 88% Huge price crash within just a few months!
Easy to surge back to $0.6 again based on its Huge Book Value --- $0.9842 a share!
Note, the 52-week-high is $5.5185 which is 9.2 Times of $0.6!
Followers
|
677
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
294653
|
Created
|
06/04/10
|
Type
|
Free
|
Moderator Value_Investor | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |